Thursday Mar 13
Trending Stocks - Cell Therapeutics Inc(NASDAQ:CTIC), Northwest ...
The company has a total market capitalization of developing DCVax personalized immune therapies for solid tumor cancers, declared that it has entered into a set of contracts for large-scale development of the storage, manufacturing, handling and distribution of its DCVax-L and DCVax-Direct products, development of infrastructure and key systems, ... (more)
Trending on the Topix Network
Wed Mar 05, 2014
Cell Therapeutics to Present at the 26th Annual ROTH Conference
Cell Therapeutics, Inc. announced today that management will present at the ROTH Capital Partners 26 Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.
Tue Mar 04, 2014
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Cell Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2013.
Cell Therapeutics Q4 revenue soars due to Baxter license payment
Cell Therapeutics Q4 revenue balloons to $32.9M versus $0 a year ago. Almost all of the revenue is due to Baxter's upfront payment of $32.4M for the license to develop and commercialize pacritinib.
Mon Mar 03, 2014
Cell Therapeutics (CTIC) to Release Quarterly Earnings on Tuesday
Cell Therapeutics is scheduled to be announcing its earnings results on Tuesday, March 4th.
Sun Mar 02, 2014
CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for...
The trial is expected to enroll up to 300 patients in , CTI reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a ... (more)
Fri Feb 28, 2014
Five Star Equities Issues New Research Reports on BEAT, CTIC, GTI and ...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
NICE Recommends Cell Therapeutics' PIXUVRI For B-Cell NHL
Seattle-based Cell Therapeutics, Inc. reported that the National Institute for Health and Care Excellence has given its final guidance recommending PIXUVRI as monotherapy for treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma including diffuse large B-cell lymphoma.
Thu Feb 27, 2014
NICE Publishes Final Guidance on PIXUVRIA
CTI estimates that there are approximately 1,600 to 1,800 people in the UK diagnosed with multiply relapsed aggressive B-cell NHL per year.
Tue Feb 25, 2014
MacReport Media RSS Feed
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From...
Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist for the year 2014 in the amount of $600,000.
Mon Feb 24, 2014
Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014
SEATTLE, Feb. 25, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. announced today that it will report its fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, after the close of the U.S. financial markets.
Hercules Offshore Losses Decrease from $121 million to $27 million...
For the twelve month period ended Dec. 31, 2013, Hercules reported a loss from continuing operations of $26.8 million, or $0.17 per diluted share, on revenue of $858.3 million, compared to a loss from continuing operations of $121.0 million, or $0.79 per diluted share, on revenue of $618.2 million for the twelve month period ended December 31, ... (more)